Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating
Truist has increased its price target for Progyny (PGNY) from $33 to $36, while reiterating a Buy rating on the stock. This adjustment follows Progyny's Q2 2026 earnings report, where the company exceeded revenue estimates. Progyny, a benefit management company specializing in fertility and …